FOR IMMEDIATE RELEASE

Compugen to Release Third Quarter 2020 Results on

Thursday, November 5, 2020

HOLON, ISRAEL, October 22, 2020 --Compugen Ltd.(Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its third quarter 2020 financial results on Thursday, November 5, 2020 before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.

To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0610 internationally. The call will also be available via live webcast through Compugen's website, located at the following link. Following the live audio webcast, a replay will be available on the Company's website.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company's lead product candidate, COM701, a first-in-classanti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is in a Phase 1 clinical study. The Company's therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. The Company is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on the Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.

Company contact:

Elana Holzman

Director, Investor Relations and Corporate Communications Compugen Ltd.

Email:elanah@cgen.com

Tel: +972 (3) 765-8124

Investor Relations contact:

Bob Yedid

LifeSci Advisors, LLC

Email:bob@lifesciadvisors.com

Tel: +1 (646) 597-6989

Media contact:

Josephine Belluardo, Ph.D.

LifeSci Communications

Email:jo@lifescicomms.com

Tel: +1 (646) 751-4361

Questo è un estratto del contenuto originale. Per continuare a leggere, accedi al documento originale.

Attachments

  • Original document
  • Permalink

Disclaimer

Compugen Ltd. published this content on 22 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 October 2020 11:39:05 UTC